Loading…
Uterine Fibroid Research and Education Act of 2020
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Uterine Fibroid Research and Education Act of 2020 This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues). Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies. In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services. Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2020 · third_quarter · Health Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019 H.R.6383 - Uterine Fibroid Research and Education Act of 2020 S.4397 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $50,000
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Issues related to patient access Issues related to pharmaceutical manufacturing Issues related to treatment of endometriosis Patent reform - S. 1416 - Affordable Prescriptions for Patients Act of 2019 Medicare Part D H.R. 748 CARES Act - Issues related to COVID-19 relief S. 4397/H.R.6383 - Uterine Fibroid Research and Education Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
Issues related to patient access Issues related to pharmaceutical manufacturing Issues related to treatment of endometriosis Patent reform - S. 1416 - Affordable Prescriptions for Patients Act of 2019 Medicare Part D H.R. 748 CARES Act - Issues related to COVID-19 relief S. 4397/H.R.6383 - Uterine Fibroid Research and Education Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
Government targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Health Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019 H.R.6383 - Uterine Fibroid Research and Education Act of 2020 S.4397 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Issues related to third party servicing of medical devices, cybersecurity, AI, focused ultrasound, the healthcare supply chain, and provider assistance. H.R. 5238 and S.2944, legislation to revise coverage of services to women under the TRICARE program to include the use of digital breast tomosynthesis in breast cancer screening and S. 4397, Uterine Fibroid Research and Education Act. Patient safety issues related to S.4473 and H.R. 7956, the Critical Medical Infrastructure Right-to-Repair Act of 2020. Issues related to PL 116-136, Coronavirus Aid, Relief and Economic Security Act (CARES Act). Discussions related to medical device user fees.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Patient access to drug treatment therapies; and drug cost and drug pricing reform efforts. H.R.3 - Lower Drug Costs Now Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019 H.R.6383 - Uterine Fibroid Research and Education Act of 2020 S.4397 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Issues related to patient access Issues related to pharmaceutical manufacturing Issues related to treatment of endometriosis Patent reform - S. 1416 - Affordable Prescriptions for Patients Act of 2019 Medicare Part D H.R. 748 CARES Act - Issues related to COVID-19 relief S. 4397/H.R.6383 - Uterine Fibroid Research and Education Act of 2020
Client expense: Not reported · Firm income: $60,000
2020 · third_quarter · Health Issues
Issues related to third party servicing of medical devices, cybersecurity, AI, focused ultrasound, the healthcare supply chain, and provider assistance. H.R. 5238 and S.2944, legislation to revise coverage of services to women under the TRICARE program to include the use of digital breast tomosynthesis in breast cancer screening and S. 4397, Uterine Fibroid Research and Education Act. Patient safety issues related to S.4473 and H.R. 7956, the Critical Medical Infrastructure Right-to-Repair Act of 2020. Issues related to PL 116-136, Coronavirus Aid, Relief and Economic Security Act (CARES Act).
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of